Clopidogrel – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:16 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Clopidogrel – CRI Report https://www.cri-report.com 32 32 Investigation Report on Chinese Clopidogrel Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinese-clopidogrel-market-2021-2025/ Fri, 23 Apr 2021 13:09:32 +0000 https://www.cri-report.com/?post_type=product&p=11229 According to CRI’s market research, the sales revenue of Clopidogrel in China has been decreasing since 2018, the sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020.

The post Investigation Report on Chinese Clopidogrel Market 2021-2025 first appeared on CRI Report.

]]> Clopidogrel is a medication that inhibits platelet aggregation and is mainly used to prevent atherosclerotic thrombosis. The original drug, Plavix, is developed by Sanofi. It enters the Chinese market in 2001. In addition to Sanofi, the other main manufacturers of Clopidogrel in the Chinese market are Salubris Pharmaceuticals, Lepu Pharmaceutical, and CSPC Ouyi Pharmaceutical.

According to CRI’s market research, the sales revenue of Clopidogrel in China has been decreasing since 2018, the sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020. The decrease in sales is mainly due to the impact of centralized procurement and the appearance of alternative drugs. Nevertheless, as the antithrombotic market keeps expanding, Clopidogrel will still have considerable annual sales in the short term. In addition, the price of Clopidogrel has been greatly reduced because of centralized procurement. Thus, some people may be more willing to choose Clopidogrel instead of other biosimilar drugs. CRI concludes that as the epidemic situation improves, Clopidogrel sales in China is expected to have a restorative growth, and it will also become more stable from 2022 to 2025.

Topics Covered:
-The impact of COVID-19 on China’s Clopidogrel market
– Sales value and volume of China’s Clopidogrel 2016-2020
– Competitive landscape of China’s Clopidogrel market
– Prices of Clopidogrel in China
– Prices of Clopidogrel in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Clopidogrel market
– Prospect of China’s Clopidogrel market from 2021 to 2025

The post Investigation Report on Chinese Clopidogrel Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on Clopidogrel in China, 2018-2022 https://www.cri-report.com/investigation-report-on-clopidogrel-in-china-2018-2022/ Fri, 17 Aug 2018 09:05:10 +0000 https://www.cri-report.com/product/import-placeholder-for-1806297/ CRI predicts that with the rising aging population, the change of lifestyle and the increasing incidence of cerebral stroke, myocardial infarction and peripheral arterial thromboembolism, the demand for Clopidogrel in the Chinese market will continue to increase.

The post Investigation Report on Clopidogrel in China, 2018-2022 first appeared on CRI Report.

]]> Description
Clopidogrel is a milestone drug in antithrombotic and antiplatelet aggregation. It was approved to be sold on the market by the FDA in 1997. The drug was jointly researched and developed by Bristol-Myers Squibb and Sanofi. Prior to the patent expiration in 2012, Plavix was ranked after Lipitor for many years and was the second best-selling drug in the world. After the patent expired, a global wave of biosimilar boomed.
Clopidogrel was early developed and marketed in China. In 2000, the Clopidogrel of Shenzhen Salubris Pharmaceuticals was first approved for registration under the trade name “Taijia”. In Sept. 2000, the Clopidogrel of Sanofi-Aventis and Bristol-Myers Squibb was granted administrative protection in China. In 2001, Sanofi-Aventis’s Clopidogrel was approved to be sold in China under the trade name “Plavix”. For years, Clopidogrel has been ranking first in China’s antithrombotic drug market, with sales revenue exceeding CNY 2 billion in 2017.
According to the CRI’s market research, Clopidogrel in the Chinese market is dominated by four companies, namely, Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Trade Name: Plavix), Shenzhen Salubris Pharmaceutical Co., Ltd. (Trade Name: Taijia), Lepu Pharmaceutical Co., Ltd. (Trade Name: Shuai Tai) and Sanofi (Trade Name: Plavix). According to the sales in 2017, Sanofi (Hangzhou) secured a market share of 52%, ranking first in the Chinese market for a long time.
CRI predicts that with the rising aging population, the change of lifestyle and the increasing incidence of cerebral stroke, myocardial infarction and peripheral arterial thromboembolism, the demand for Clopidogrel in the Chinese market will continue to increase.

Topics Covered:
Development History of Clopidogrel in Chinese Market
Development Environment of Clopidogrel in China
Sales of Clopidogrel in China
Major Clopidogrel Manufacturers in Chinese Market
Sale Price of Clopidogrel in Chinese Market

Prospects of Chinese Clopidogrel Market, 2018-2022

 

The post Investigation Report on Clopidogrel in China, 2018-2022 first appeared on CRI Report.

]]>